For help on how to get the results you want, see our search tips.
1967 results
-
List item
Human medicine European public assessment report (EPAR): VidPrevtyn Beta (updated)
SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain), COVID-19 virus infection
Date of authorisation: 10/11/2022,
, Authorised, Last updated: 30/11/2022
-
List item
Human medicine European public assessment report (EPAR): Azomyr
desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
Date of authorisation: 15/01/2001, Revision: 50, Authorised, Last updated: 04/10/2022 -
List item
Human medicine European public assessment report (EPAR): Beyfortus (updated)
nirsevimab,
Date of authorisation: 31/10/2022,, Authorised, Last updated: 15/11/2022
-
List item
Human medicine European public assessment report (EPAR): Enjaymo (updated)
sutimlimab, Hemolysis; Anemia, Hemolytic, Autoimmune
Date of authorisation: 15/11/2022,, 
, Authorised, Last updated: 17/11/2022
-
List item
Human medicine European public assessment report (EPAR): Teriflunomide Mylan (updated)
Teriflunomide, Multiple Sclerosis, Relapsing-Remitting
, Authorised, Last updated: 22/11/2022
-
List item
Human medicine European public assessment report (EPAR): Sorafenib Accord (updated)
Sorafenib tosilate, Carcinoma, Hepatocellular; Carcinoma, Renal Cell
Date of authorisation: 09/11/2022,, Authorised, Last updated: 25/11/2022
-
List item
Human medicine European public assessment report (EPAR): Teriflunomide Accord (updated)
Teriflunomide, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 09/11/2022,, Authorised, Last updated: 14/11/2022
-
List item
Human medicine European public assessment report (EPAR): Melatonin Neurim (updated)
melatonin, Sleep Initiation and Maintenance Disorders
Date of authorisation: 07/11/2022, Authorised, Last updated: 25/11/2022 -
List item
Human medicine European public assessment report (EPAR): Ximluci (updated)
ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
Date of authorisation: 09/11/2022,, 
, Authorised, Last updated: 29/11/2022
-
List item
Human medicine European public assessment report (EPAR): Livtencity (updated)
Maribavir, Cytomegalovirus Infections
Date of authorisation: 09/11/2022,, , Authorised, Last updated: 01/12/2022
-
List item
Human medicine European public assessment report (EPAR): Illuzyce
lutetium (177Lu) chloride, Radionuclide Imaging
Date of authorisation: 15/09/2022, Authorised, Last updated: 21/09/2022 -
List item
Human medicine European public assessment report (EPAR): Nulibry
fosdenopterin hydrobromide dihydrate, Metal Metabolism, Inborn Errors
Date of authorisation: 15/09/2022,, , Authorised, Last updated: 30/09/2022
-
List item
Human medicine European public assessment report (EPAR): Amvuttra
vutrisiran sodium, Amyloid Neuropathies, Familial
Date of authorisation: 15/09/2022,, , Authorised, Last updated: 12/10/2022
-
List item
Human medicine European public assessment report (EPAR): Vabysmo
Faricimab, Wet Macular Degeneration; Macular Edema; Diabetes Complications
Date of authorisation: 15/09/2022,, Authorised, Last updated: 13/10/2022
-
List item
Human medicine European public assessment report (EPAR): Opdualag
nivolumab, Relatlimab, Melanoma
Date of authorisation: 15/09/2022,, Authorised, Last updated: 17/10/2022
-
List item
Human medicine European public assessment report (EPAR): Tecvayli
Teclistamab, Multiple Myeloma
Date of authorisation: 23/08/2022,, 
, Authorised, Last updated: 20/10/2022
-
List item
Human medicine European public assessment report (EPAR): Tezspire (updated)
tezepelumab, Asthma
Date of authorisation: 19/09/2022,, Revision: 1, Authorised, Last updated: 09/11/2022
-
List item
Human medicine European public assessment report (EPAR): Thalidomide Lipomed
Thalidomide, Multiple Myeloma
Date of authorisation: 19/09/2022, Authorised, Last updated: 20/10/2022 -
List item
Human medicine European public assessment report (EPAR): Lupkynis
Voclosporin, Lupus Nephritis
Date of authorisation: 15/09/2022,, Authorised, Last updated: 20/09/2022
-
List item
Human medicine European public assessment report (EPAR): Mounjaro (updated)
Tirzepatide, Diabetes Mellitus, Type 2
Date of authorisation: 15/09/2022, Authorised, Last updated: 25/11/2022 -
List item
Human medicine European public assessment report (EPAR): Scemblix
asciminib hydrochloride, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 25/08/2022,, , Authorised, Last updated: 07/09/2022
-
List item
Human medicine European public assessment report (EPAR): Vegzelma
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022,, , Revision: 1, Authorised, Last updated: 26/09/2022
-
List item
Human medicine European public assessment report (EPAR): Ranivisio
ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
Date of authorisation: 25/08/2022,, , Revision: 1, Authorised, Last updated: 05/10/2022
-
List item
Human medicine European public assessment report (EPAR): Vyvgart (updated)
Efgartigimod alfa, Myasthenia Gravis
Date of authorisation: 10/08/2022,, , Revision: 2, Authorised, Last updated: 22/11/2022
-
List item
Human medicine European public assessment report (EPAR): Sunlenca
Lenacapavir sodium, HIV Infections
Date of authorisation: 17/08/2022,, Authorised, Last updated: 25/08/2022